ERBB2 and breast cancer: Among all the references, the top three most cited articles are as follows: “Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer” (n = 1344), “Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients with HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study” (n = 546), and “HER2-Low Breast Cancer: Pathological and Clinical Landscape” (n = 462), as shown in Table 7.